Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

Background: The study aims to address the challenge of accurately identifying patients with ovarian cancer who would benefit from poly-ADP ribose inhibitors (PARPi) as first-line maintenance therapy. While BRCA1/2-mutated epithelial ovarian cancer (EOC) patients have shown significant benefits from PARPi treatment, the efficacy in homologous recombination deficient (HRD) patients remains inconclusive. Current assays used to estimate HR status do not effectively differentiate between patients who benefit most from PARPi and those who do not, making it inefficient to treat all patients. There i

Trial Details

NCT ID
NCT06377267
Phase
PHASE2
Sponsor
Vall d'Hebron Institute of Oncology
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Bevacizumab
  • Olaparib
Locations (sample)
  • Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Patient with newly diagnosed high- grade serous or endometrioid Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer. I-3-3 At an…
  • Patient who has completed prior to enrollment first line platinum-taxane chemotherapy:
  • Platinum-taxane based regimen must have consisted of
  • minimum of 6 treatment cycles and a maximum of 8. However, if platinum-based therapy must be discontinued early as a result of non-hematological to…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →